论文部分内容阅读
目的:比较两种口服铁剂力蜚能(多糖铁复合物胶囊)与福乃得(硫酸亚铁-维生素C、B复合物)分别与重组人红细胞生成素(EPO)联合应用,治疗伴有缺铁肾性贫血的有效性和安全性。方法:采用随机、对照、开放性研究,102例患者分为力蜚能组52例和福乃得组50例。力蜚能组:口服力蜚能1粒,每日2次,共8周;福乃得组:口服福乃得1粒,每日2次,共8周。两组患者均使用EPO治疗,剂量为每周75~100IU/kg,皮下注射,观察比较两组患者贫血治疗的疗效,铁代谢指标的变化及不良反应发生情况。结果:治疗前两组间在男、女性别比例、年龄、体重和血红蛋白、血清铁、转铁蛋白饱和度等方面均无显著差异。治疗后两组Hb较治疗前明显升高,而力蜚能组Hb上升幅度高于福乃得组;两组患者治疗后血清铁和转铁蛋白饱和度均高于治疗前,治疗后力蜚能组血清铁和转铁蛋白饱和度均高于福乃得组。两组患者血清BUN、Scr、AST ALP、ALB等均无变化。两组患者无不良反应发生。但力蜚能组不良反应发生率低于福乃得组。结论:力蜚能是一种治疗伴有缺铁的肾性贫血的有效而安全的药物,其升高Hb的作用比硫酸亚铁更快,且不良反应发生率更低。
OBJECTIVE: To compare the effects of two oral iron dosing agents (polysaccharide iron complex capsules) and fortune (ferrous sulfate-vitamin C, B complex) with recombinant human erythropoietin (EPO) Efficacy and safety of iron deficiency anemia. Methods: A randomized, controlled and open study was conducted. 102 patients were divided into two groups: Li-Gui-Neng Group (n = 52) and Fortune Group (n = 50). Force power group: Oral power can 1, 2 times a day for a total of 8 weeks; Fortune group: oral Funeral 1, 2 times a day for a total of 8 weeks. The two groups of patients were treated with EPO, the dose was 75 ~ 100IU / kg per week, subcutaneously. The curative effect of anemia treatment, changes of iron metabolism indexes and adverse reactions were observed and compared between the two groups. Results: Before treatment, there was no significant difference in male and female sex ratio, age, body weight, hemoglobin, serum iron and transferrin saturation. After treatment, the Hb levels in both groups were significantly higher than those before treatment, while the Hb levels in Lixingneng group were higher than those in the Fortune group. The serum iron and transferrin saturation in both groups were significantly higher than those before treatment and after treatment Serum iron and transferrin saturation were higher than the group of Fortune. Serum BUN, Scr, AST ALP, ALB and other two groups had no change. No adverse reactions occurred in both groups. However, the incidence of adverse reactions in the Nifedipine group was lower than the Fx group. CONCLUSION: Nifedipine is an effective and safe drug for the treatment of renal anemia associated with iron deficiency. Its effect of increasing Hb is faster than that of ferrous sulfate and the incidence of adverse reactions is lower.